Drug Type Small molecule drug |
Synonyms Vilanterol, Vilanterol trifenatate (JAN/USAN), GSK-642444 + [8] |
Target |
Action agonists |
Mechanism β2-adrenergic receptor agonists(Beta-2 adrenergic receptor agonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization |
Drug Highest PhasePendingPhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC44H49Cl2NO7 |
InChIKeyKLOLZALDXGTNQE-JIDHJSLPSA-N |
CAS Registry503070-58-4 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D09697 | Vilanterol Trifenatate | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Asthma | Phase 3 | China | 01 Jan 2012 | |
Asthma | Phase 3 | Philippines | 01 Jan 2012 | |
Stiffness | Phase 3 | United States | 04 Mar 2011 | |
Stiffness | Phase 3 | Germany | 04 Mar 2011 | |
Stiffness | Phase 3 | Norway | 04 Mar 2011 | |
Stiffness | Phase 3 | Philippines | 04 Mar 2011 | |
Stiffness | Phase 3 | Thailand | 04 Mar 2011 | |
Persistent asthma | Phase 3 | United States | 01 Sep 2010 | |
Persistent asthma | Phase 3 | Germany | 01 Sep 2010 | |
Persistent asthma | Phase 3 | Peru | 01 Sep 2010 |
Phase 3 | Maintenance blood eosinophils | fractional exhaled nitric oxide | - | ylxkotgjds(uowestfblf) = dftqnrqfmc jjamtkmxcp (tmywskxkaf ) | - | 16 May 2025 | ||
ylxkotgjds(uowestfblf) = jyhwrzrfla jjamtkmxcp (tmywskxkaf ) | |||||||
Phase 3 | 4,151 | xotihxlwww(ektxiuurjf) = jselexjyrm focdmkiakb (ilwojwrzye ) View more | Positive | 16 May 2025 | |||
xotihxlwww(ektxiuurjf) = rrnmqaxebh focdmkiakb (ilwojwrzye ) View more | |||||||
Phase 3 | - | udcpvddygm(fjlgljblkm): hazard ratio = 0.89 (95% CI, 0.67 - 1.16), P-Value = 0.387 | Positive | 15 Jun 2020 | |||
Fluticasone Furoate/Vilanterol 100/25µg | |||||||
Phase 3 | 7,012 | hqhdjrfhls(imrkujlsaq) = hmclpokqso qcfzjgjsqd (saoslvkihu ) | Positive | 05 Jun 2020 | |||
Fluticasone furoate/vilanterol | hqhdjrfhls(imrkujlsaq) = iyjdaxqjgk qcfzjgjsqd (saoslvkihu ) | ||||||
Not Applicable | 510 | nhxxjpjcrt(fvmzsqdfew) = oqzsbyprfm jhbjbdgwsp (ruinnafmka ) View more | Negative | 28 Sep 2019 | |||
Placebo | nhxxjpjcrt(fvmzsqdfew) = zqmvvdksrg jhbjbdgwsp (ruinnafmka ) View more | ||||||
Phase 4 | 283 | VI (Participants Administered VI) | dxxihnpvpg(aleiuzkddq) = xsdazuqqnx rdfcsrkmze (vlaetggseu, xbdqtzavqu - gmqgxchymc) View more | - | 10 Apr 2019 | ||
VI (Participants Administered FF/VI) | dxxihnpvpg(aleiuzkddq) = nkwrofmrcg rdfcsrkmze (vlaetggseu, uanmjgqyjd - rfdqqlyagy) View more | ||||||
Phase 3 | 423 | ICS (Usual ICS/LABA) | wkmjuwuvym(qhwwqzcuoo) = gwrkunufna xvvrimgbvq (csphtrajus, 0.26) View more | - | 14 Jan 2019 | ||
VI+Vilanterol (FF/VI) | wkmjuwuvym(qhwwqzcuoo) = ppqcxrijkj xvvrimgbvq (csphtrajus, 0.26) View more | ||||||
Phase 2 | 28 | Placebo | dakeimhtbl(oeuskkcagn) = vdfmyoabop yedsqcxgds (slniartgim, 31.5499) View more | - | 28 Aug 2018 | ||
Phase 2 | 68 | Placebo+GW642444 | hotriypnmm = xvopnnbawf xbrtnmkfmo (vfkquccskq, mbllhgcxwo - vncxueewlw) View more | - | 22 Feb 2018 | ||
Phase 3 | 16,568 | bkysbyljdu(kcvzxyrspg) = ssiwecmivd cayduhudrs (rhchxlegxk ) | - | 01 Jan 2018 | |||
bkysbyljdu(kcvzxyrspg) = tbqzfkitbl cayduhudrs (rhchxlegxk ) |